Liu and colleagues examined 1024 glioma patients and found higher CTLA4 expression in aggressive gliomas, particularly those with higher grades, IDH-wild type status, and the mesenchymal molecular subtype. The gene discussed is IDH1; the disease is central nervous system cancer.